Anthem Biosciences Ltd ANTHEM
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ₹800.75
- Day Range
- ₹783.35–817.80
- 52-Week Range
- ₹585.00–977.55
- Bid/Ask
- ₹803.00 / ₹812.80
- Shares Outstanding
- 563.53M
- Market Cap
- ₹458.04B
- Volume/Avg
- 535,896 / 706,538
Key Statistics
- Price/Earnings (Normalized)
- 80.08
- Price/Sales
- 23.10
- Dividend Yield (Trailing)
- 0.25%
- Dividend Yield (Forward)
- 0.25%
- Dividend Payment Schedule
- Aug
- Total Yield
- 0.25%
Company Profile
Anthem Biosciences Ltd is mainly engaged in discovering, developing, manufacturing, and commercializing biopharmaceutical products that address unmet needs and provide biological solutions to improve industrial performance in all areas. The company offers its CRDMO services to biotech, pharmaceutical, and other companies for the development of large and small drug molecules, and also runs a products business offering specialty ingredients like fermentation products, peptides, lipids, probiotics, APIs, biosimilars, etc. Its reportable segments are: Contract Research Development and Manufacturing Services (CRDMO), which derives maximum revenue, and Specialty Ingredients. Geographically, the company generates maximum revenue from Europe, followed by North America, India, and other regions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 3,302
- Website
- https://www.anthembio.com
Valuation
|
Metric
|
ANTHEM
|
|---|---|
Price/Earnings (Normalized) | 80.08 |
Price/Book Value | 15.17 |
Price/Sales | 23.10 |
Price/Cash Flow | 66.08 |
Price/Earnings
ANTHEM
Financial Strength
|
Metric
|
ANTHEM
|
|---|---|
Quick Ratio | 4.70 |
Current Ratio | 5.54 |
Interest Coverage | 127.84 |
Quick Ratio
ANTHEM
Profitability
|
Metric
|
ANTHEM
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ANTHEM
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@Sjn$t# | LOCK|rdv@ | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%<psh^x | LOCK|jG%^! | $83B | |||
| Moderna Inc
MRNA
| LOCK|Czfv#$< | LOCK|#> | $80B | |||
| argenx SE ADR
ARGX
| LOCK|z<#%c$ | LOCK|%$q | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|&snl@&f | LOCK|?# | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|^t!<Tf | LOCK|X#HWh | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<!>ngb! | LOCK|&TVG@ | $28B | |||
| Incyte Corp
INCY
| LOCK|K<bQx$ | LOCK|q^q | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|bw?%qn | LOCK|MFG | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|DQ^@YC | LOCK|?& | $14B |
United States